State Street Corp Rallybio Corp Transaction History

State Street Corp

$2.41 Trillion
Q3 2024

A detailed history of State Street Corp transactions in Rallybio Corp stock. As of the latest transaction made, State Street Corp holds 62,072 shares of RLYB stock, worth $63,934. This represents 0.0% of its overall portfolio holdings.

Number of Shares

62,072

Previous 65,222 4.83%

Holding current value

$63,934

Previous $87,000 17.24%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$1.09 - $1.45 $3,433 - $4,567	-3,150 Reduced 4.83%	62,072 $72,000
Q2 2024 Aug 14, 2024	SELL	$1.34 - $2.98 $600,984 - $1.34 Million	-448,496 Reduced 87.3%	65,222 $87,000
Q1 2024 May 15, 2024	BUY	$1.25 - $2.4 $6,435 - $12,355	5,148 Added 1.01%	513,718 $950,000
Q4 2023 Feb 14, 2024	BUY	$1.91 - $4.39 $7,151 - $16,436	3,744 Added 0.74%	508,570 $1.22 Million
Q3 2023 Nov 14, 2023	BUY	$3.37 - $6.16 $39,584 - $72,355	11,746 Added 2.38%	504,826 $1.7 Million
Q2 2023 Aug 14, 2023	BUY	$4.31 - $8.89 $944,269 - $1.95 Million	219,088 Added 79.96%	493,080 $2.79 Million
Q1 2023 May 15, 2023	BUY	$4.37 - $8.75 $18,257 - $36,557	4,178 Added 1.55%	273,992 $1.56 Million
Q4 2022 Feb 14, 2023	BUY	$4.67 - $14.86 $80,426 - $255,918	17,222 Added 6.82%	269,814 $1.77 Million
Q3 2022 Nov 15, 2022	BUY	$7.54 - $14.56 $27,460 - $53,027	3,642 Added 1.46%	252,592 $3.66 Million
Q2 2022 Aug 15, 2022	BUY	$6.26 - $13.65 $565,760 - $1.23 Million	90,377 Added 56.99%	248,950 $1.88 Million
Q1 2022 May 16, 2022	BUY	$6.91 - $15.04 $585,608 - $1.27 Million	84,748 Added 114.8%	158,573 $1.11 Million
Q4 2021 Feb 14, 2022	BUY	$9.3 - $19.91 $225,450 - $482,658	24,242 Added 48.89%	73,825 $704,000
Q3 2021 Nov 15, 2021	BUY	$10.83 - $23.4 $536,983 - $1.16 Million	49,583 New	49,583 $872,000

Others Institutions Holding RLYB

# of Institutions

Shares Held

31.9M

Call Options Held

Put Options Held

View Full List

About Rallybio Corp

Ticker RLYB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,132,000
Market Cap $33.1M
Description
Rallybio Corporation, a clinical-stage biotechnology company, engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that is in Phase I clinical trial for the prevention of feta...

More about RLYB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.

Account

State Street Corp Rallybio Corp Transaction History